Autologous Micrografts Containing Nanovesicles, Exosomes, and Follicle Stem Cells in Androgenetic Alopecia: In Vitro and In Vivo Analysis Through a Mu

[Dimitri001]

https://link.springer.com/article/10.1007/s00266-024-04439-7

Background​

The use of micrografts (MCGs) containing human follicle mesenchymal stem cells (HF-MSCs) is a hair loss (hair loss) treatment that needs to be standardized as seems to have promising effects on hair regrowth (HR-G) also thanks to the presence of extracellular vesicles (EVs).

Objectives​

The study aims to report both the in vivo results, obtained in patients affected by androgenic alopecia (Androgenetic Alopecia) treated using MCGs, and in vitro analysis characterizing the EVs.

Methods​

A multicentric, retrospective, observational, evaluator-blinded study was conducted. Eighty-three Androgenetic Alopecia patients were initially enrolled [52 suffering from male pattern hair loss (MPHL) at stages I–III vertex by the Norwood–Hamilton scale and 31 suffering from female PHL (FPHL) at stages I–II by the Ludwig scale]. Sixty patients (20 females and 40 males) were treated and analyzed after exclusion and inclusion criteria assessment. The in vivo HR-G was evaluated through photography, physician’s, and patient’s global assessment scales, in addition to standardized photo-trichograms, during a follow-up for 1 year, while the in vitro analysis was performed through a quantitative, morphological, and dimensional characterization of the EVs population using transmission electron microscopy (TEM) and fluorescent microscopy.

Results​

A hair density (HD) increase of 28 ± 4 hairs/cm2 at T4 after 12 months in the targeted area (TA) of FPHL, compared with the baseline, was observed using computerized trichograms with a statistically significant difference (SSD) in hair regrowth (HR-G) (p = 0.0429). Regarding MPHL, an HD increase of 30 ± 5 hairs/cm2 at T4 after 12 months in the TA was observed with an SSD in HR-G (p = 0.0012). The presence of EVs and their interaction with the surrounding cellular population were demonstrated.

Conclusions​

MCGs containing HF-MSCs and exosomes may fill in as a safe and viable alternative treatment against hair loss in mild and moderate degrees of Androgenetic Alopecia both in MPHL and in FPHL.

 

[Hope111]

lol only 4 hairs per cm2, minoxidil alone gets at least triple that. This condition is truly nature's ultimate joke.

I understand that it is +/- 4

 

[Jakejr]

The key is the hair stem cells..which produce hair follicles & hairs..
Scientists are beginning to harvest stem cells in “Petri dishes” in the laboratory & subject them to chemicals, peptides, growth factors, molecules, micro electro stimulations to see if they can grow hair faster …
male pattern baldness is when areas of the scalp are being signaled to not grow or Telogen phase.
This signaling can be done in many ways. DHT signals the hairs on scalp to not grow. The good news is the hairs can be signaled to grow again to override the OFF DHT signal

 

[Hope111]

what medication will do that?

 

[Jakejr]

One way which has recent clinical studies is by micro electro current. There are a few others.. Men with their constant flow of high DHT finally signals the hair stem cells to turn off. However the stem cells can be signaled to turn back on in spite of this constant high DHT by micro electro stimulation.
That explains why bald eunuchs often don’t regrow back their hair despite low DHT levels. Their hair stem cells switch are still in the OFF position. They need a jolt to turn them back ON to produce hairs..
I’ve started reading the studies & they say essentially the same thing..
So my current thinking is this is the key to hair growth. Luckily there are options now for men rather than the hormonal route..

 

[Hope111]

Would we be talking about niosten?

 

[Jakejr]

Niosten has a compelling story. The founder has a PhD in regenerative medicine. He originally was working on stem cells for cancer research. He developed a way to extract hair stem cells and test them in laboratory. When he tried micro current he made his discovery. He then created a device for the public and has had a clinical study. A bigger clinical study is starting with grants from European governments..